Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2022 earnings per share (EPS) estimates for shares of Seelos Therapeutics in a report released on Thursday, November 17th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($0.65) per share for the year, down from their previous estimate of ($0.48). The consensus estimate for Seelos Therapeutics’ current full-year earnings is ($0.65) per share. Cantor Fitzgerald also issued estimates for Seelos Therapeutics’ FY2023 earnings at ($0.60) EPS.
Seelos Therapeutics Stock Down 3.3 %
Shares of SEEL opened at $0.82 on Monday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 1.36. Seelos Therapeutics has a 52-week low of $0.48 and a 52-week high of $2.12. The company has a market cap of $87.44 million, a PE ratio of -1.03 and a beta of 2.06. The business has a fifty day moving average of $0.99 and a 200 day moving average of $0.88.
Hedge Funds Weigh In On Seelos Therapeutics
About Seelos Therapeutics
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
- Get a free copy of the StockNews.com research report on Seelos Therapeutics (SEEL)
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.